More Young People Are Dying of Colon Cancer
September 15, 2017
MS and the Importance of Finding Your Peace of Mind
September 15, 2017
Show all

New Drug Approved for all Hep C Strains

There is a newly approved medication for hepatitis C.

A new weapon is now available in the battle against chronic hepatitis C, and it offers several benefits over its predecessors—most notably, shortened treatment time. The drug, called Mavyret, is a once-daily, ribavirin-free treatment requiring just 8 weeks rather than the standard 12 weeks.

Mavyret showed an overall 98% cure rate across all major genotypes and can also be used to treat patients with genotype 1 infection who were not successfully treated with other direct-acting antiviral treatments previously, according to FDA’s Center for Drug Evaluation and Research. The most common side effects were headache and tiredness.

This new hep C treatment is from Chicago-based pharmaceutical maker AbbVie, which has reportedly priced the pan-genotypic medication at $26,400 for the entire course of treatment. This compares to list prices of nearly $28,000 for AbbVie’s own Viekira Pak and $31,500 for Gilead’s Harvoni.

Read full article: New Drug Approved for all Hep C Strains – Mediware Information Systems

Read Full Article: New Drug Approved for all Hep C Strains – Mediware Information Systems

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.